Published in Cancer Weekly, March 28th, 2000
"Patients with advanced NSCLC and abnormal p53 function were enrolled onto cohorts receiving escalating dose levels of Adp53 (1x106 to 1x1011 plaque-forming units [PFU])," wrote J. Nemunaitis and colleagues, Physician Reliance Network Research, Inc., Texas, USA.
Nemunaitis et al. published their study in Journal of Clinical Oncology ("Adenovirus-mediated p53 gene...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.